drugset / Trial / NCT05551897

A Study to Assess the Pharmacokinetics of Camizestrant (AZD9833) When Administered Alone and in Combination With Itraconazole

NCT05551897

Phase 1 Completed 14 enrolled AstraZeneca Parexel · collab
NaSingle-groupOpen-labelOther

Summary

This study will be conducted in healthy post-menopausal female subjects to assess the pharmacokinetics (PK) of Camizestrant (AZD9833) when administered alone and in combination with Itraconazole.

Timeline

Start
2022-10-04
Primary completion
2022-12-28
Completion
2022-12-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Camizestrant Other / unclassified Oral
Subject Itraconazole Small molecule

Indications

No indication recorded.